This page contains exclusive content for the member of the following sections: TTS, CTS, IXA
Presenter: Gaetan, Delcroix, Miami, United States
Authors: Gaetan Delcroix1, Elisa Garbayo2, Laurence Sindji3, Olivier Thomas3, Claire Vanpouille-Box3, Gianluca D'Ippolito1, Claudia Montero-Menei3, Paul Schiller1
111
Pharmacologically active microcarriers enhance the therapeutic effects of MIAMI cell transplanted in hemi-parkinsonian rats
Gaetan Delcroix1, Elisa Garbayo2, Laurence Sindji3, Olivier Thomas3, Claire Vanpouille-Box3, Gianluca D’Ippolito1, Claudia Montero-Menei3, Paul Schiller1
1University of Miami Tissue Bank (UMTB), University of Miami, Miami, FL, United States; 2Pharmacy and Pharmaceutical Technology Department, University of Navarra, Pamplona, Spain; 3INSERM U646, University of Angers, Angers, France
L-DOPA, currently the most efficient therapeutic treatment for Parkinson’s disease (PD), aims at replenishing the amount of dopamine decreased in the degenerated patient’s striatum. However, long-term treatment with L-DOPA slowly becomes less effective and shows numerous undesirable side effects. In the present study, we assessed the effectiveness of a tissue engineering approach which combined marrow-isolated adult multilineage inducible (MIAMI) cells, a subpopulation of human MSCs, and biomimetic drug releasing microcarrier scaffolds, prior to their transplantation in a rat model of PD. The scaffolds, named pharmacologically active microcarriers (PAMs), are biodegradable and biocompatible poly(lactic-co-glycolic acid) microspheres, coated by a biomimetic surface and releasing a therapeutic protein, which acts on the cells conveyed on their surface and on their microenvironment. In this study, PAMs were coated with laminin and engineered to release neurotrophin 3 (NT3), which stimulates the neuronal-like differentiation of MIAMI cells and promotes neuronal survival. MIAMI cells were subjected to a dopaminergic induction protocol and the dopaminergic-induced (DI)-MIAMI cells were adhered to PAMs in vitro. These complexes were grafted in the partially dopaminergic-deafferented striatum of rats. This treatment led to a strong reduction of the amphetamine-induced rotational behavior together with a protection/repair of the nigrostriatal pathway. These effects were assumed to result from the observed enhanced survival of DI-MIAMI cells when combined to PAMs, as well as from their ability to secrete a wide range of growth factors and chemokines in situ. In addition, overexpression of Tyrosine Hydroxylase by DI-MIAMI cells transplanted in combination with PAMs may also have contributed to the observed functional recovery. To our knowledge, this is the first study that successfully combines adult stem cells and tissue engineering to protect and repair dopaminergic neurons in a rat model of PD, and we expect to evaluate this strategy in larger animal models of PD in the future.
By viewing the material on this site you understand and accept that:
The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada